Sigbjørn Smeland

  • Head of division; MD, PhD
  • +47 23 07 59 31
 

Publications 2024

Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
[Not Available]
Tidsskr Nor Laegeforen, 144 (1)
DOI 10.4045/tidsskr.23.0740, PubMed 38258713

Nordengen AL, Zheng C, Krutto A, Kværner AS, Alavi DT, Henriksen HB, Henriksen C, Smeland S, Bøhn SK, Paur I, Shaposhnikov S, Collins AR, Blomhoff R (2024)
Effect of a personalized intensive dietary intervention on base excision repair (BER) in colorectal cancer patients: Results from a randomized controlled trial
Free Radic Biol Med, 218, 178-189 (in press)
DOI 10.1016/j.freeradbiomed.2024.04.211, PubMed 38588903

Schlander M, van Harten W, Retèl VP, Pham PD, Vancoppenolle JM, Ubels J, López OS, Quirland C, Maza F, Aas E, Crusius B, Escobedo A, Franzen N, Fuentes-Cid J, Hernandez D, Hernandez-Villafuerte K, Kirac I, Paty A, Philip T, Smeland S, Sullivan R, Vanni E, Varga S, Vermeulin T, Eckford RD (2024)
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions
Lancet Oncol, 25 (4), e152-e163
DOI 10.1016/S1470-2045(23)00636-8, PubMed 38547899

Publications 2023

Alavi DT, Henriksen HB, Lauritzen PM, Zucknick M, Bøhn SK, Henriksen C, Paur I, Smeland S, Blomhoff R (2023)
Effect of a one-year personalized intensive dietary intervention on body composition in colorectal cancer patients: Results from a randomized controlled trial
Clin Nutr ESPEN, 57, 414-422
DOI 10.1016/j.clnesp.2023.06.037, PubMed 37739688

Hjermstad MJ, Aass N, Gravli TH, Smeland S, Kaasa S (2023)
[Patient-centred cancer care]
Tidsskr Nor Laegeforen, 143 (1)
DOI 10.4045/tidsskr.22.0668, PubMed 36655956

Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
EBioMedicine, 97, 104829
DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Kvaerner AS, Andersen AR, Henriksen HB, Knudsen MD, Johansen AMW, Hjartåker A, Bøhn SK, Paur I, Wiedswang G, Smeland S, Rounge TB, Blomhoff R, Berstad P (2023)
Associations of the 2018 World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR) cancer prevention recommendations with stages of colorectal carcinogenesis
Cancer Med, 12 (13), 14806-14819
DOI 10.1002/cam4.6119, PubMed 37212529

Nordengen AL, Kværner AS, Krutto A, Alavi DT, Henriksen HB, Henriksen C, Raastad T, Smeland S, Bøhn SK, Shaposhnikov S, Collins AR, Blomhoff R (2023)
DNA base oxidation in relation to TNM stages and chemotherapy treatment in colorectal cancer patients 2-9 months post-surgery
Free Radic Biol Med, 212, 174-185
DOI 10.1016/j.freeradbiomed.2023.12.016, PubMed 38141887

Palmerini E, Reichardt P, Hall KS, Bertulli R, Bielack SS, Comandone A, Egerer G, Hansmeier A, Kevric M, Carretta E, Hansson L, Jebsen N, Eriksson M, Bruland ØS, Donati DM, Ibrahim T, Smeland S, Ferrari S (2023)
Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.)
Cancer, 129 (22), 3564-3573
DOI 10.1002/cncr.34964, PubMed 37530385

Skaali T, Blomhoff R, Lindemann K, Smeland S, Bruheim K, Seland M, Thorsen L (2023)
Self-reported distress and problems after treatment for gynecological cancer - Correlation between a short screening tool and longer measures of anxiety/depression and health-related quality of life
Acta Obstet Gynecol Scand, 103 (2), 387-395
DOI 10.1111/aogs.14709, PubMed 37991142

Publications 2022

Budde A, Baust K, Weinhold L, Bernstein M, Bielack S, Dhooge C, Hjorth L, Janeway KA, Jenney M, Krailo MD, Marina N, Nagarajan R, Smeland S, Sydes MR, De Vos P, Whelan J, Wiener A, Calaminus G, Schmid M (2022)
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma
Eur J Cancer, 170, 209-235
DOI 10.1016/j.ejca.2022.03.018, PubMed 35689897

Budde A, Baust K, Weinhold L, Bernstein M, Bielack S, Dhooge C, Hjorth L, Janeway KA, Jenney M, Krailo MD, Marina N, Nagarajan R, Smeland S, Sydes MR, De Vos P, Whelan J, Wiener A, Calaminus G, Schmid M (2022)
Erratum to 'Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma' [Eur J Cancer 170 (2022) 209-235]
Eur J Cancer, 177, 208-209
DOI 10.1016/j.ejca.2022.06.053, PubMed 36347760

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045

Monsen KV, Fosså SD, Myklebust TÅ, Smeland S, Dahl AA, Stensvold A (2022)
Long-term satisfaction with curative treatment and follow-up in prostate cancer survivors
Acta Oncol, 61 (3), 357-362
DOI 10.1080/0284186X.2021.2006775, PubMed 35103559

Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai KZ, Vaage JT, Nissen-Meyer LSH, Sund F, Wader KF, Bjornevik AT, Meyer PA, Nygaard GO, König M, Smeland S, Lund-Johansen F, Olweus J, Kolstad A (2022)
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Br J Haematol, 197 (6), 697-708
DOI 10.1111/bjh.18149, PubMed 35254660

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529

Publications 2021

Alavi DH, Henriksen HB, Lauritzen PM, Kværner AS, Sakinis T, Langleite TM, Henriksen C, Bøhn SK, Paur I, Wiedswang G, Smeland S, Blomhoff R (2021)
Quantification of adipose tissues by Dual-Energy X-Ray Absorptiometry and Computed Tomography in colorectal cancer patients
Clin Nutr ESPEN, 43, 360-368
DOI 10.1016/j.clnesp.2021.03.022, PubMed 34024541

Hompland I, Ferrari S, Bielack S, Palmerini E, Hall KS, Picci P, Hecker-Nolting S, Donati DM, Blattmann C, Bjerkehagen B, Staals E, Kager L, Gambarotti M, Kühne T, Eriksson M, Ferraresi V, Kevric M, Biagini R, Baumhoer D, Brosjø O, Comandone A, Schwarz R, Bertulli R, Kessler T, Hansson L et al. (2021)
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study
Eur J Cancer, 151, 150-158
DOI 10.1016/j.ejca.2021.04.017, PubMed 33990016

Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland Å (2021)
COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
Front Oncol, 11, 652535
DOI 10.3389/fonc.2021.652535, PubMed 33842366

Maehle PM, Hajdarevic S, Håland E, Aarhus R, Smeland S, Mørk BE (2021)
Exploring the triggering process of a cancer care reform in three Scandinavian countries
Int J Health Plann Manage, 36 (6), 2231-2247
DOI 10.1002/hpm.3278, PubMed 34291498

Mæhle PM, Hanto IKS, Simensen VC, Smeland S (2021)
Mind the Differences: How Diagnoses and Hospital Characteristics Influence Coordination in Cancer Patient Pathways
Int J Environ Res Public Health, 18 (16)
DOI 10.3390/ijerph18168818, PubMed 34444567

Mæhle PM, Smeland S (2021)
Implementing cancer patient pathways in Scandinavia how structuring might affect the acceptance of a politically imposed reform
Health Policy, 125 (10), 1340-1350
DOI 10.1016/j.healthpol.2021.08.008, PubMed 34493379

Publications 2020

Bärebring L, Kværner AS, Skotnes M, Henriksen HB, Skjetne AJ, Henriksen C, Ræder H, Paur I, Bøhn SK, Wiedswang G, Smeland S, Blomhoff R (2020)
Use of bioelectrical impedance analysis to monitor changes in fat-free mass during recovery from colorectal cancer- a validation study
Clin Nutr ESPEN, 40, 201-207
DOI 10.1016/j.clnesp.2020.09.021, PubMed 33183537

Kværner AS, Harnæs H, Alavi DH, Bärebring L, Henriksen HB, Guren MG, Lauritzen PM, Eggesbø HB, Wiedswang G, Smeland S, Blomhoff R (2020)
Should calculation of chemotherapy dosage for bowel cancer be based on body composition?
Tidsskr Nor Laegeforen, 140 (8)
DOI 10.4045/tidsskr.19.0769, PubMed 32463187

Mæhle PM, Small Hanto IK, Smeland S (2020)
Practicing Integrated Care Pathways in Norwegian Hospitals: Coordination through Industrialized Standardization, Value Chains, and Quality Management or an Organizational Equivalent to Improvised Jazz Standards
Int J Environ Res Public Health, 17 (24)
DOI 10.3390/ijerph17249199, PubMed 33317088

Terrisse S, Karamouza E, Parker CC, Sartor AO, James ND, Pirrie S, Collette L, Tombal BF, Chahoud J, Smeland S, Erikstein B, Pignon JP, Fizazi K, Le Teuff G, MORPHEP Collaborative Group (2020)
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials
JAMA Oncol, 6 (2), 206-216
DOI 10.1001/jamaoncol.2019.4097, PubMed 31830233

Vatne Monsen K, Fosså SD, Dahl AA, Myklebust TÅ, Smeland S, Stensvold A (2020)
Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life
Scand J Urol, 55 (1), 9-16
DOI 10.1080/21681805.2020.1854343, PubMed 33349097

Publications 2019

Calaminus G, Jenney M, Hjorth L, Baust K, Bernstein M, Bielack S, Vos P, Hogendoorn PCW, Jovic G, Krailo M, Kreitz K, Marina N, Popoola BO, Sauerland C, Smeland S, Teske C, Schweinitz CV, Whelan J, Wiener A, Sydes MR, Nagarajan R (2019)
Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy
JMIR Res Protoc, 8 (8), e14406
DOI 10.2196/14406, PubMed 31573951

Jha AK, Neupane P, Pradhan M, Sharma KS, Shrestha S, Sigdel PR, Smeland S, Bruland ØS (2019)
Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy
J Glob Oncol, 5, 1-10
DOI 10.1200/JGO.19.00015, PubMed 30917070

Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R et al. (2019)
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
Eur J Cancer, 109, 36-50
DOI 10.1016/j.ejca.2018.11.027, PubMed 30685685

Publications 2018

Ferrari S, Bielack SS, Smeland S, Longhi A, Egerer G, Sundby Hall K, Donati D, Kevric M, Brosjö O, Comandone A, Werner M, Monge O, Palmerini E, Berdel WE, Bjerkehagen B, Paioli A, Lorenzen S, Eriksson M, Gambarotti M, Tunn PU, Jebsen NL, Cesari M, von Kalle T, Ferraresi V, Schwarz R et al. (2018)
EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma
Tumori, 104 (1), 30-36
DOI 10.5301/tj.5000696, PubMed 29218692

Henriksen HB, Berntsen S, Paur I, Zucknick M, Skjetne AJ, Bøhn SK, Henriksen C, Smeland S, Carlsen MH, Blomhoff R (2018)
Validation of two short questionnaires assessing physical activity in colorectal cancer patients
BMC Sports Sci Med Rehabil, 10, 8
DOI 10.1186/s13102-018-0096-2, PubMed 29854408

Henriksen HB, Carlsen MH, Paur I, Berntsen S, Bøhn SK, Skjetne AJ, Kværner AS, Henriksen C, Andersen LF, Smeland S, Blomhoff R (2018)
Relative validity of a short food frequency questionnaire assessing adherence to the Norwegian dietary guidelines among colorectal cancer patients
Food Nutr Res, 62
DOI 10.29219/fnr.v62.1306, PubMed 29545734

Høland M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, Mandahl N, van den Berg E, Smeland S, Mertens F, Sundby Hall K, Picci P, Sveen A, Lothe RA (2018)
Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53
Mod Pathol, 31 (11), 1694-1707
DOI 10.1038/s41379-018-0074-y, PubMed 29946184

Kværner AS, Minaguchi J, Yamani NE, Henriksen C, Ræder H, Paur I, Henriksen HB, Wiedswang G, Smeland S, Blomhoff R, Collins AR, Bøhn SK (2018)
DNA damage in blood cells in relation to chemotherapy and nutritional status in colorectal cancer patients-A pilot study
DNA Repair (Amst), 63, 16-24
DOI 10.1016/j.dnarep.2018.01.005, PubMed 29414050

Paur I, Slattholm MA, Ryel AL, Smeland S (2018)
Proper nutrition is important for cancer patients
Tidsskr. Nor. Laegeforen., 138 (11), 1004-1006

Paur I, Slåttholm MA, Ryel AL, Smeland S (2018)
[Proper nutrition is important for cancer patients]
Tidsskr Nor Laegeforen, 138 (11)
DOI 10.4045/tidsskr.18.0072, PubMed 29947205

Ræder H, Henriksen C, Bøhn SK, O de Fey Vilbo AR, Henriksen HB, Kværner AS, Rolid K, Paur I, Smeland S, Blomhoff R (2018)
Agreement between PG-SGA category and fat-free mass in colorectal cancer patients
Clin Nutr ESPEN, 27, 24-31
DOI 10.1016/j.clnesp.2018.07.005, PubMed 30144889

Publications 2017

Henriksen HB, Ræder H, Bøhn SK, Paur I, Kværner AS, Billington SÅ, Eriksen MT, Wiedsvang G, Erlund I, Færden A, Veierød MB, Zucknick M, Smeland S, Blomhoff R (2017)
The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-based multicentre randomized controlled trial
BMC Cancer, 17 (1), 83
DOI 10.1186/s12885-017-3072-4, PubMed 28137255

Ræder H, Kværner AS, Henriksen C, Florholmen G, Henriksen HB, Bøhn SK, Paur I, Smeland S, Blomhoff R (2017)
Validity of bioelectrical impedance analysis in estimation of fat-free mass in colorectal cancer patients
Clin Nutr, 37 (1), 292-300
DOI 10.1016/j.clnu.2016.12.028, PubMed 28122662

Publications 2016

Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS et al. (2016)
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Lancet Oncol, 17 (10), 1396-1408
DOI 10.1016/S1470-2045(16)30214-5, PubMed 27569442

Russnes KM, Möller E, Wilson KM, Carlsen M, Blomhoff R, Smeland S, Adami HO, Grönberg H, Mucci LA, Bälter K (2016)
Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study
BMC Cancer, 16, 438
DOI 10.1186/s12885-016-2486-8, PubMed 27400803

Thorsen L, Dahl AA, Nystad R, Kiserud CE, Geirdal AØ, Smeland S (2016)
Baseline characteristics in female cancer patients with unimproved work status after an outpatient rehabilitation program and health changes during the intervention
Springerplus, 5 (1), 1009
DOI 10.1186/s40064-016-2663-x, PubMed 27398282

Publications 2015

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P et al. (2015)
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
J Clin Oncol, 33 (20), 2279-87
DOI 10.1200/JCO.2014.60.0734, PubMed 26033801

Kolberg M, Høland M, Lind GE, Ågesen TH, Skotheim RI, Hall KS, Mandahl N, Smeland S, Mertens F, Davidson B, Lothe RA (2015)
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection
Mol Oncol, 9 (6), 1129-39
DOI 10.1016/j.molonc.2015.02.005, PubMed 25769404

Publications 2014

Bruheim M, Woods KV, Smeland S, Nortvedt MW (2014)
An educational program to transition oncology nurses at the Norwegian Radium Hospital to an evidence-based practice model: development, implementation, and preliminary outcomes
J Cancer Educ, 29 (2), 224-32
DOI 10.1007/s13187-013-0575-9, PubMed 24197689

Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Sundby Hall K, van den Berg E, Mertens F, Smeland S, Picci P, Lothe RA (2014)
Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis
Neuro Oncol, 17 (1), 63-9
DOI 10.1093/neuonc/nou140, PubMed 25038505

Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G et al. (2014)
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
Ann Oncol, 26 (2), 407-14
DOI 10.1093/annonc/mdu526, PubMed 25421877

Publications 2013

Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S, Johannesen TB, Fosså SD (2013)
Incidence and mortality of second sarcomas - a population-based study
Eur J Cancer, 49 (15), 3292-302
DOI 10.1016/j.ejca.2013.05.017, PubMed 23787025

Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, Kager L, Kühne T, Sydes M, Gelderblom H, Ferrari S, Picci P, Smeland S, Eriksson M, Petrilli AS, Bleyer A, Thomas DM (2013)
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis
J Clin Oncol, 31 (18), 2303-12
DOI 10.1200/JCO.2012.43.8598, PubMed 23669227

Russnes KM, Wilson KM, Epstein MM, Kasperzyk JL, Stampfer MJ, Kenfield SA, Smeland S, Blomhoff R, Giovannucci EL, Willett WC, Mucci LA (2013)
Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Follow-Up Study
Int J Cancer, 134 (5), 1156-65
DOI 10.1002/ijc.28438, PubMed 23959920

Publications 2012

Bøhn SK, Russnes KM, Sakhi AK, Thoresen M, Holden M, Moskaug JØ, Myhrstad MC, Olstad OK, Smeland S, Blomhoff R (2012)
Stress associated gene expression in blood cells is related to outcome in radiotherapy treated head and neck cancer patients
BMC Cancer, 12, 426
DOI 10.1186/1471-2407-12-426, PubMed 23009663

Kolberg M, Høland M, Agesen TH, Brekke HR, Liestøl K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA (2012)
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1
Neuro Oncol, 15 (2), 135-47
DOI 10.1093/neuonc/nos287, PubMed 23161774

Luksch R, Tienghi A, Hall KS, Fagioli F, Picci P, Barbieri E, Gandola L, Eriksson M, Ruggieri P, Daolio P, Lindholm P, Prete A, Bisogno G, Tamburini A, Grignani G, Abate ME, Podda M, Smeland S, Ferrari S (2012)
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation
Ann Oncol, 23 (11), 2970-2976
DOI 10.1093/annonc/mds117, PubMed 22771824

Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S (2012)
Bother problems in prostate cancer patients after curative treatment
Urol Oncol, 31 (7), 1067-78
DOI 10.1016/j.urolonc.2011.12.020, PubMed 22341412

Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M (2012)
Cancer risk with folic acid supplements: a systematic review and meta-analysis
BMJ Open, 2 (1), e000653
DOI 10.1136/bmjopen-2011-000653, PubMed 22240654

Publications 2011

Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Smeland S, Fosså SD (2011)
Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival?
Br J Cancer, 106 (2), 297-306
DOI 10.1038/bjc.2011.559, PubMed 22173669

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Smeland S, Bruland OS, Hjorth L, Brosjö O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Björk O, Alvegaard TA (2011)
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years
Acta Orthop, 82 (2), 211-6
DOI 10.3109/17453674.2011.566141, PubMed 21434784

Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S (2011)
Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones
Prostate, 72 (6), 668-76
DOI 10.1002/pros.21470, PubMed 21809351

Publications 2010

Brekke HR, Ribeiro FR, Kolberg M, Agesen TH, Lind GE, Eknaes M, Hall KS, Bjerkehagen B, van den Berg E, Teixeira MR, Mandahl N, Smeland S, Mertens F, Skotheim RI, Lothe RA (2010)
Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group
J Clin Oncol, 28 (9), 1573-82
DOI 10.1200/JCO.2009.24.8989, PubMed 20159821

Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, Alvegard TA, Brach Del Prever A, Tamburini A, Alberghini M, Gandola L, Mercuri M, Capanna R, Mapelli S, Prete A, Carli M, Picci P, Barbieri E, Bacci G, Smeland S (2010)
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
Ann Oncol, 22 (5), 1221-1227
DOI 10.1093/annonc/mdq573, PubMed 21059639

Sakhi AK, Bøhn SK, Smeland S, Thoresen M, Smedshaug GB, Tausjø J, Svilaas A, Karlsen A, Russnes KM, Svilaas T, Blomhoff R (2010)
Postradiotherapy plasma lutein, alpha-carotene, and beta-carotene are positively associated with survival in patients with head and neck squamous cell carcinoma
Nutr Cancer, 62 (3), 322-8
DOI 10.1080/01635580903441188, PubMed 20358469

Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S (2010)
Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center
Acta Oncol, 50 (3), 408-14
DOI 10.3109/0284186X.2010.492236, PubMed 20586661

Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M (2010)
The role of interferons in the treatment of osteosarcoma
Pediatr Blood Cancer, 54 (3), 350-4
DOI 10.1002/pbc.22136, PubMed 19902521

Publications 2009

Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, Domanski HA, Mandahl N, Liestøl K, Smeland S, Danielsen HE, Mertens F, Lothe RA (2009)
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors
Neuro Oncol, 11 (5), 514-28
DOI 10.1215/15228517-2008-127, PubMed 19182148

Bruland ØS, Bauer H, Alvegaard T, Smeland S (2009)
Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience
Cancer Treat Res, 152, 309-18
DOI 10.1007/978-1-4419-0284-9_16, PubMed 20213398

Bruland ØS, Høifødt H, Hall KS, Smeland S, Fodstad Ø (2009)
Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients
Cancer Treat Res, 152, 509-15
DOI 10.1007/978-1-4419-0284-9_30, PubMed 20213412

Jetne V, Kvaløy S, Smeland S, Johannesen TB, Tveit KM (2009)
[Use of radiotherapy in South-Eastern Norway Regional Health Authority]
Tidsskr Nor Laegeforen, 129 (24), 2602-5
DOI 10.4045/tidsskr.09.0331, PubMed 20029555

Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, Butterfass-Bahloul T, Calaminus G, Bernstein M (2009)
International collaboration is feasible in trials for rare conditions: the EURAMOS experience
Cancer Treat Res, 152, 339-53
DOI 10.1007/978-1-4419-0284-9_18, PubMed 20213400

Sakhi AK, Russnes KM, Thoresen M, Bastani NE, Karlsen A, Smeland S, Blomhoff R (2009)
Pre-radiotherapy plasma carotenoids and markers of oxidative stress are associated with survival in head and neck squamous cell carcinoma patients: a prospective study
BMC Cancer, 9, 458
DOI 10.1186/1471-2407-9-458, PubMed 20025747

Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA (2009)
Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol
Acta Orthop., 80 334, 60-66

Smeland S, Wiebe T, Monge OR, Brosjo O, Bohling T, Hjorth L, Hall KS, Jakobson A, Alvegaard TA (2009)
Treatment of localized Ewing sarcoma family of tumors The Scandinavian Sarcoma Group experience
Acta Orthop., 80, 75-78

Publications 2008

Bielack SS, Marina N, Ferrari S, Helman LJ, Smeland S, Whelan JS, Reaman GH (2008)
Osteosarcoma: the same old drugs or more?
J Clin Oncol, 26 (18), 3102-3; author reply 3104-5
DOI 10.1200/JCO.2008.17.1108, PubMed 18565904

Bjerkehagen B, Smeland S, Walberg L, Skjeldal S, Hall KS, Nesland JM, Småstuen MC, Fosså SD, Saeter G (2008)
Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital
Acta Oncol, 47 (8), 1475-82
DOI 10.1080/02841860802047387, PubMed 18607853

Fosså SD, Dahl AA, Smeland S, Thorsen L, Loge JH (2008)
[Rehabilitation after cancer]
Tidsskr Nor Laegeforen, 128 (22), 2615-6
PubMed 19023358

Publications 2006

Blomhoff R, Grønli KS, Smeland S (2006)
Fruktbar kunnskap for mannens edlere deler
Birkeland Publications, [Oslo], 152 s.
BIBSYS 062030884, ISBN 978-82-997423-0-6

Sakhi AK, Russnes KM, Smeland S, Blomhoff R, Gundersen TE (2006)
Simultaneous quantification of reduced and oxidized glutathione in plasma using a two-dimensional chromatographic system with parallel porous graphitized carbon columns coupled with fluorescence and coulometric electrochemical detection
J Chromatogr A, 1104 (1-2), 179-89
DOI 10.1016/j.chroma.2005.11.129, PubMed 16376913

Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S (2006)
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol
Int J Oncol, 29 (6), 1459-68
PubMed 17088985

Storlazzi CT, Brekke HR, Mandahl N, Brosjö O, Smeland S, Lothe RA, Mertens F (2006)
Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours
J Pathol, 209 (4), 492-500
DOI 10.1002/path.1998, PubMed 16721726

Publications 2005

Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O (2005)
Hematogenous micrometastases in osteosarcoma patients
Clin Cancer Res, 11 (13), 4666-73
DOI 10.1158/1078-0432.CCR-05-0165, PubMed 16000559

Bøhn SK, Smeland S, Sakhi AK, Thoresen M, Russnes KM, Tausjø J, Svilaas A, Svilaas T, Blomhoff R (2005)
Post-radiotherapy plasma total glutathione is associated to outcome in patients with head and neck squamous cell carcinoma
Cancer Lett, 238 (2), 240-7
DOI 10.1016/j.canlet.2005.07.027, PubMed 16157445

Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G, Italian and Scandinavian Sarcoma Groups (2005)
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups
J Clin Oncol, 23 (34), 8845-52
DOI 10.1200/JCO.2004.00.5785, PubMed 16246977

Müller CR, Smeland S, Bauer HC, Saeter G, Strander H (2005)
Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series
Acta Oncol, 44 (5), 475-80
DOI 10.1080/02841860510029978, PubMed 16118081

Staff AC, Holven K, Løken EB, Sygnestveit K, Vollset SE, Smeland S (2005)
[Does folic acid have effects on other health problems than neural tube defects?]
Tidsskr Nor Laegeforen, 125 (4), 438-41
PubMed 15742017

Staff AC, Løken EB, Holven K, Sygnestveit K, Vollset SE, Smeland S (2005)
[Effects of public initiatives aimed at reducing neural tube defects with folic acid supplementation]
Tidsskr Nor Laegeforen, 125 (4), 435-7
PubMed 15742016

Publications 2004

Alvegård TA, Bauer H, Blomqvist C, Rydholm A, Smeland S (2004)
The Scandinavian Sarcoma Group--background, organization and the SSG Register--the first 25 years
Acta Orthop Scand Suppl, 75 (311), 1-7
DOI 10.1080/00016470410001708250, PubMed 15188658

Bauer HC, Alvegård TA, Berlin O, Erlanson M, Kalén A, Lindholm P, Gustafson P, Smeland S, Trovik CS (2004)
The Scandinavian Sarcoma Group Register 1986-2001
Acta Orthop Scand Suppl, 75 (311), 8-10
DOI 10.1080/00016470410001708260, PubMed 15188659

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
Ann Oncol, 15 (7), 1072-8
DOI 10.1093/annonc/mdh262, PubMed 15205201

Smeland S, Wiebe T, Brosjö O, Böhling T, Alvegård TA (2004)
Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience
Acta Orthop Scand Suppl, 75 (311), 87-91
DOI 10.1080/00016470410001708370, PubMed 15188670

Smeland S, Wiebe T, Böhling T, Brosjö O, Jonsson K, Alvegård TA (2004)
Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience
Acta Orthop Scand Suppl, 75 (311), 92-8
DOI 10.1080/00016470410001708380, PubMed 15188671

Publications 2003

Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousses S, Mandahl N, Soeter G, Nesland JM, Smeland S, Kallioniemi OP, Lothe RA (2003)
Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome
J Clin Oncol, 21 (24), 4586-91
DOI 10.1200/JCO.2003.07.067, PubMed 14673046

Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fosså SD (2003)
Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study
Int J Radiat Oncol Biol Phys, 56 (5), 1397-404
DOI 10.1016/s0360-3016(03)00274-8, PubMed 12873686

Smeland S, Muller C, Saeter G (2003)
Reply to comment on "Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders"
Eur. J. Cancer, 39 (17), 2567-2568
DOI 10.1016/j.ejca.2003.08.019

Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, Stenwig AE, Willén H, Holmström T, Follerås G, Brosjö O, Kivioja A, Jonsson K, Monge O, Saeter G (2003)
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders
Eur J Cancer, 39 (4), 488-94
DOI 10.1016/s0959-8049(02)00747-5, PubMed 12751380

Publications 2002

Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002)
[Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma]
Tidsskr Nor Laegeforen, 122 (4), 364-9
PubMed 11915663

Thune I, Smeland S (2002)
Kan fysisk aktivitet forebygge kreft?
In Fysisk aktivitet og helse: temahefte, Foreningen, Oslo, S. 49-54
BIBSYS 021845735

Thune I, Smeland S (2002)
Er fysisk aktivitet av betydning i behandling og rehabilitering av kreftpasienter
In Fysisk aktivitet og helse: temahefte, Foreningen, Oslo, S. 59-61
BIBSYS 021845786

Publications 2000

Thune I, Smeland S (2000)
[Can physical activity prevent cancer?]
Tidsskr Nor Laegeforen, 120 (27), 3296-301
PubMed 11187174

Thune I, Smeland S (2000)
[Is physical activity important in treatment and rehabilitation of cancer patients?]
Tidsskr Nor Laegeforen, 120 (27), 3302-4
PubMed 11187175

Thune I, Smeland S (2000)
Kan fysisk aktivitet forebygge kreft?
In Tidsskrift for Den norske legeforening, Foreningen, Oslo, 120(2000)nr. 27, S. 3296-3301
BIBSYS 010293922

Thune I, Smeland S (2000)
Er fysisk aktivitet av betydning i behandling og rehabilitering av kreftpasienter
In Tidsskrift for Den norske legeforening, Foreningen, Oslo, 120(2000)nr. 27, S. 3302-3304
BIBSYS 01029404x

Publications 1999

Hagen E, Myhre AM, Smeland S, Halvorsen B, Norum KR, Blomhoff R (1999)
Uptake of vitamin A in macrophages from physiologic transport proteins: role of retinol-binding protein and chylomicron remnants
J Nutr Biochem, 10 (6), 345-52
DOI 10.1016/s0955-2863(99)00013-3, PubMed 15539309

Publications 1998

Reppe S, Smeland S, Moskaug JO, Blomhoff R (1998)
Retinol-induced secretion of human retinol-binding protein in yeast
FEBS Lett, 427 (2), 213-9
DOI 10.1016/s0014-5793(98)00428-1, PubMed 9607314

Smeland S (1998)
Metabolism of plasma retinol-binding protein
Institute for Nutrition Research, University of Oslo, [Oslo], 1 b. (flere pag.)
BIBSYS 981161375, ISBN 82-91061-80-7

Publications 1997

Natarajan V, Smeland S, Moskaug JO, Kamiyama S, Masushige S, Kato S, Blomhoff R (1997)
Role of the C-termini of human and chicken plasma retinol-binding proteins
Eur J Cell Biol, 73 (4), 316-20
PubMed 9270874

Smeland S, Kolset SO, Lyon M, Norum KR, Blomhoff R (1997)
Binding of perlecan to transthyretin in vitro
Biochem J, 326 ( Pt 3) (Pt 3), 829-36
DOI 10.1042/bj3260829, PubMed 9307034

Publications 1995

Malaba L, Smeland S, Senoo H, Norum KR, Berg T, Blomhoff R, Kindberg GM (1995)
Retinol-binding protein and asialo-orosomucoid are taken up by different pathways in liver cells
J Biol Chem, 270 (26), 15686-92
DOI 10.1074/jbc.270.26.15686, PubMed 7797569

Smeland S, Bjerknes T, Malaba L, Eskild W, Norum KR, Blomhoff R (1995)
Tissue distribution of the receptor for plasma retinol-binding protein
Biochem J, 305 ( Pt 2) (Pt 2), 419-24
DOI 10.1042/bj3050419, PubMed 7832754

Publications 1993

Senoo H, Smeland S, Malaba L, Bjerknes T, Stang E, Roos N, Berg T, Norum KR, Blomhoff R (1993)
Transfer of retinol-binding protein from HepG2 human hepatoma cells to cocultured rat stellate cells
Proc Natl Acad Sci U S A, 90 (8), 3616-20
DOI 10.1073/pnas.90.8.3616, PubMed 8386378

Publications 1992

Blomhoff R, Senoo H, Smeland S, Bjerknes T, Norum KR (1992)
Cellular uptake of vitamin A
J Nutr Sci Vitaminol (Tokyo), Spec No, 327-30
DOI 10.3177/jnsv.38.special_327, PubMed 1338447

Publications 1986

Maeland JA, Smeland S (1986)
Exemplification of serological cross-reactivity of Neisseria lipopolysaccharides
Acta Pathol Microbiol Immunol Scand B, 94 (4), 223-9
DOI 10.1111/j.1699-0463.1986.tb03045.x, PubMed 2428203

Publications 1985

Smeland S (1985)
Undersøkelse over antistoff mot Salmonella minnesota: Re LPS, et felles antigen for Gram negative staver
Regionsykehuset i Trondheim, Mikrobiologisk laboratorium, Trondheim, 20 s.
BIBSYS 865000328

Page visits: 16484